

# Barbro K Linderholm

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7914240/barbro-k-linderholm-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

45  
papers

1,266  
citations

17  
h-index

35  
g-index

48  
ext. papers

1,433  
ext. citations

5.2  
avg, IF

3.63  
L-index

#	Paper	IF	Citations
45	Abstract OT2-30-01: Nordictrip, a translational randomized phase-3 study exploring the effect of the addition of capecitabine to carboplatinum-based chemotherapy in early triple negative breast cancer, ClinicalTrials.gov Identifier: NCT04335669. <i>Cancer Research</i> , <b>2022</b> , 82, OT2-30-01-OT2-30-01	10.1	
44	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , <b>2021</b> , 11, 2796-2811	24.4	10
43	Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. <i>Npj Breast Cancer</i> , <b>2021</b> , 7, 98	7.8	1
42	Delta NT-proBNP predicts cardiotoxicity in HER2-positive breast cancer patients treated with trastuzumab. <i>Acta Oncologica</i> , <b>2021</b> , 60, 475-481	3.2	2
41	Breaking Bad News in Cancer Care: Ethiopian Patients Want More Information Than What Family and the Public Want Them to Have. <i>JCO Global Oncology</i> , <b>2021</b> , 7, 1341-1348	3.7	
40	Survival patterns of invasive lobular and invasive ductal breast cancer in a large population-based cohort with two decades of follow up. <i>Breast</i> , <b>2021</b> , 59, 294-300	3.6	3
39	Discordance of PIK3CA and TP53 mutations between breast cancer brain metastases and matched primary tumors. <i>Scientific Reports</i> , <b>2021</b> , 11, 23548	4.9	1
38	Personalised medicine and the decision to withhold chemotherapy in early breast cancer with intermediate risk of recurrence - a systematic review and meta-analysis. <i>European Journal of Clinical Pharmacology</i> , <b>2020</b> , 76, 1199-1211	2.8	2
37	A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns. <i>Breast Cancer Research and Treatment</i> , <b>2020</b> , 182, 643-654	4.4	8
36	Clinical outcome of patients with brain metastases from breast cancer - A population based study over 21 years. <i>Breast</i> , <b>2020</b> , 50, 113-124	3.6	8
35	Communicative challenges among physicians, patients, and family caregivers in cancer care: An exploratory qualitative study in Ethiopia. <i>PLoS ONE</i> , <b>2020</b> , 15, e0230309	3.7	9
34	Person and Family Centeredness in Ethiopian Cancer Care: Proposal for a Project for Improving Communication, Ethics, Decision Making, and Health. <i>JMIR Research Protocols</i> , <b>2020</b> , 9, e16493	2	0
33	Efficacy and tolerability of metronomic chemotherapy in patients with metastatic breast cancer - an international experience in West Sweden and in the South of Ireland. <i>Cancer Treatment and Research Communications</i> , <b>2020</b> , 25, 100237	2	
32	Immune gene expression and response to chemotherapy in advanced breast cancer. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 480-488	8.7	20
31	Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 168, 349-355	4.4	5
30	Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. <i>Modern Pathology</i> , <b>2017</b> , 30, 509-518	9.8	22
29	The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?. <i>Breast</i> , <b>2017</b> , 33, 191-199	3.6	3

28	Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. <i>European Journal of Cancer</i> , <b>2017</b> , 82, 219-227	7.5	53
27	PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 7225-7231	12.9	6
26	Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 146-57	12.9	29
25	Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer. <i>Clinical Proteomics</i> , <b>2015</b> , 12, 8	5	26
24	Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. <i>Annals of Oncology</i> , <b>2015</b> , 26, 81-88	10.3	57
23	Molecular profiling of male breast cancer - lost in translation?. <i>International Journal of Biochemistry and Cell Biology</i> , <b>2014</b> , 53, 526-35	5.6	28
22	Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106, djt376	9.7	62
21	Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. <i>Nature Communications</i> , <b>2013</b> , 4, 2175	17.4	47
20	Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy. <i>Medical Oncology</i> , <b>2013</b> , 30, 415	3.7	6
19	Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 131-7	7.5	31
18	Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 125, 457-65	4.4	17
17	A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophosphamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer. <i>Acta Oncologica</i> , <b>2011</b> , 50, 35-41	3.2	14
16	Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy. <i>Acta Oncologica</i> , <b>2009</b> , 48, 504-13	3.2	3
15	Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer. <i>Breast</i> , <b>2008</b> , 17, 484-91	3.6	16
14	An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells. <i>Molecular Cancer Research</i> , <b>2008</b> , 6, 1630-8	6.6	77
13	Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen. <i>European Journal of Cancer</i> , <b>2006</b> , 42, 1104-12	7.5	43
12	Sequencing of the tumor suppressor gene TP 53. <i>Methods in Molecular Medicine</i> , <b>2006</b> , 120, 389-401		2
11	Weekly taxanes--a leap forward or a minute progress?. <i>Acta Oncologica</i> , <b>2004</b> , 43, 5-7	3.2	3

10	Thrombospondin-1 expression in relation to p53 status and VEGF expression in human breast cancers. <i>European Journal of Cancer</i> , <b>2004</b> , 40, 2417-23	7.5	11
9	Cellular and Tissue Markers in Solid Tumors <b>2004</b> , 181-213		
8	Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2003</b> , 82, 147-54	4.4	95
7	Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers. <i>Clinical Breast Cancer</i> , <b>2003</b> , 4, 340-7	3	60
6	A population-based study on the first forty-eight breast cancer patients receiving trastuzumab (Herceptin) on a named patient basis in Sweden. <i>Acta Oncologica</i> , <b>2002</b> , 41, 276-81	3.2	12
5	p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. <i>International Journal of Cancer</i> , <b>2000</b> , 89, 51-62	7.5	121
4	Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 1423-31	2.2	224
3	Alterations of the immunoglobulin heavy chain locus in progressive B-cell lymphomas. <i>Acta Oncologica</i> , <b>1998</b> , 37, 193-200	3.2	4
2	Expression of Cyclin E and the Cyclin-Dependent Kinase Inhibitor p27 in Malignant Lymphomas Prognostic Implications. <i>Blood</i> , <b>1998</b> , 92, 770-777	2.2	118
1	Expression of Cyclin E and the Cyclin-Dependent Kinase Inhibitor p27 in Malignant Lymphomas Prognostic Implications. <i>Blood</i> , <b>1998</b> , 92, 770-777	2.2	7